{"url_path":"/sec/asth/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1083446/0001193125-26-213157-index.html","accession_number":"0001193125-26-213157","cik":"0001083446","ticker":"ASTH","issuer_name":"Astrana Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1083446/0001193125-26-213157-index.html","primary_entity_key":"0001083446","primary_entity_name":"Astrana Health, Inc."},"word_count":75,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\nRule 10b5-1 Trading Plans\n\nDuring the quarter ended March 31, 2026, none of the Company’s directors or executive officers adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).\n\n50\n\n[Table of Contents](#table_of_contents)"}